ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
7,756.10
-0.39%
S&P ASX All Technology
3,436.10
-0.42%
Brent Oil
70.715
0.04%
US Dollar vs AUD
1.58377
0.20%
Bitcoin
83,637.86
-0.05%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Akebia Therapeutics Inc (AKBA) Share Price

Akebia Therapeutics Inc

Akebia Therapeutics Inc (AKBA)

NASDAQ
1.92
-0.01
(-0.52%)
Closed 13 March 7:00AM
Delayed by 15 minutes
1.9112
-0.0088
(-0.46%)
After Hours: 10:30AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.9112
Bid
1.91
Offer
1.95
Volume
3,479,663
1.91 Day's Range 1.99
0.80 52 Week Range 2.48
Market Cap
416.988M
Previous Close
1.93
Open
1.97
Last Trade
5
@
1.95
Last Trade Time
Financial Volume
US$ 6,802,285
VWAP
1.9549
Average Volume (3m)
2,188,948
Shares Outstanding
218,181,202
Dividend Yield
-
PE Ratio
-8.07
Earnings Per Share (EPS)
-0.24
Revenue
194.62M
Net Profit
-51.93M

About Akebia Therapeutics Inc

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment... Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.akebia.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Akebia Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AKBA. The last closing price for Akebia Therapeutics was US$1.93. Over the last year, Akebia Therapeutics shares have traded in a share price range of US$ 0.80 to US$ 2.48.

Akebia Therapeutics currently has 218,181,202 shares in issue. The market capitalisation of Akebia Therapeutics is US$421.09 million. Akebia Therapeutics has a price to earnings ratio (PE ratio) of -8.07.

Ask ADVFN Intelligence (AI)

AKBA Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 March 2025
AKBA (-0.52%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 March 2025
AKBA (-0.52%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
04 March 2025
AKBA (-0.52%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
04 March 2025
AKBA (-0.52%)

Form 8-K - Current report
Edgar (US Regulatory)
08 February 2025
AKBA (-0.52%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 February 2025
AKBA (-0.52%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 February 2025
AKBA (-0.52%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 February 2025
AKBA (-0.52%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.07123.869565217391.841.971.8122899791.89624901CS
4-0.1738-8.335731414872.0852.171.7221791261.88344247CS
120.03121.659574468091.882.411.71521889481.98057739CS
260.473732.95304347831.43752.411.2420071541.84899974CS
520.461231.80689655171.452.480.829374231.58613225CS
156-0.7688-28.68656716422.682.680.24135291360.96377633CS
260-4.4888-70.13756.413.780.24136993352.13808135CS

AKBA - Frequently Asked Questions (FAQ)

What is the current Akebia Therapeutics share price?
The current share price of Akebia Therapeutics is US$ 1.9112
How many Akebia Therapeutics shares are in issue?
Akebia Therapeutics has 218,181,202 shares in issue
What is the market cap of Akebia Therapeutics?
The market capitalisation of Akebia Therapeutics is USD 421.09M
What is the 1 year trading range for Akebia Therapeutics share price?
Akebia Therapeutics has traded in the range of US$ 0.80 to US$ 2.48 during the past year
What is the PE ratio of Akebia Therapeutics?
The price to earnings ratio of Akebia Therapeutics is -8.07
What is the cash to sales ratio of Akebia Therapeutics?
The cash to sales ratio of Akebia Therapeutics is 2.15
What is the reporting currency for Akebia Therapeutics?
Akebia Therapeutics reports financial results in USD
What is the latest annual turnover for Akebia Therapeutics?
The latest annual turnover of Akebia Therapeutics is USD 194.62M
What is the latest annual profit for Akebia Therapeutics?
The latest annual profit of Akebia Therapeutics is USD -51.93M
What is the registered address of Akebia Therapeutics?
The registered address for Akebia Therapeutics is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Akebia Therapeutics website address?
The website address for Akebia Therapeutics is www.akebia.com
Which industry sector does Akebia Therapeutics operate in?
Akebia Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CRVOCervoMed Inc
US$ 6.15
(160.59%)
154M
ZENAZenaTech Inc
US$ 4.5505
(61.94%)
6.88M
OPRXOptimizeRx Corporation
US$ 6.265
(51.33%)
13.1M
SSPEW Scripps Company
US$ 2.05
(43.36%)
16.99M
GRPNGroupon Inc
US$ 13.9807
(43.10%)
10.42M
HITHealth In Tech Inc
US$ 1.32
(-82.31%)
16.73M
SPHLSpringview Holdings Ltd
US$ 1.24
(-79.33%)
10.7M
APDNApplied DNA Sciences Inc
US$ 0.0619
(-57.89%)
35.11M
ZYXIZynex Inc
US$ 3.39
(-51.57%)
3.82M
HEPAHepion Pharmaceuticals Inc
US$ 0.0488
(-41.90%)
79.16M
STISolidion Technology Inc
US$ 0.174899
(38.70%)
584.7M
NVDANVIDIA Corporation
US$ 115.74
(6.42%)
323.86M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 9.1432
(15.59%)
222.8M
VSTEVast Renewable Ltd
US$ 0.6182
(23.66%)
193.78M
CRVOCervoMed Inc
US$ 6.15
(160.59%)
158.89M

AKBA Discussion

View Posts
Monksdream Monksdream 4 days ago
AKBA under $2
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
AKBA test that 2.50 from a year ago
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
AKBA breaking out
👍️0
glenn1919 glenn1919 2 months ago
AKBA....................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
akba........................https://stockcharts.com/h-sc/ui?s=akba&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
AKBA.............................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
AKBA.................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 months ago
AKBA.....................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
AKBA BIO BEAST INTO FDA
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
AKBA BEASTING LONG...FDA APPROVED DRUG COMES TO MARKET IN JAN
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
AKBA BUILDING 1.79 BREAK IS COMING
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
AKBA GAPPING AND READY FOR 1.79
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
AKBA BACK IN PLAY UNTIL JAN 2025...FDA COMING
👍️0
glenn1919 glenn1919 7 months ago
AKBA.....................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 months ago
AKBA................................https://stockcharts.com/h-sc/ui?s=ARKB&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 months ago
AKBA......................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 8 months ago
AKBA...........................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Krspecialized Krspecialized 8 months ago
I believe the current news releases may have answered your question. GLTA
👍️0
Toofuzzy Toofuzzy 9 months ago
Why do you say we have a gold mine here ?

Toofuzzy
👍️0
Krspecialized Krspecialized 9 months ago
There's no doubt we have a gold mine here, and at some point it will be load up time. Figuring out when is the big question!
👍️0
eyeownu eyeownu 10 months ago
SCARY MOVIE
👍️0
eyeownu eyeownu 10 months ago
https://journey.ct.events/view/a825b116-e5ee-4e76-ad8d-2e9e9116aa21 tomorrows web cast
👍️0
eyeownu eyeownu 10 months ago
added 2k@ 1.11
👍️ 1
glenn1919 glenn1919 10 months ago
AKBA................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 11 months ago
AKBA under $2

👍️0
eyeownu eyeownu 11 months ago
ask is stacked! someone needs to slap it.
👍️0
eyeownu eyeownu 11 months ago
$AKBA RELOAD
👍️0
Firestorm22 Firestorm22 11 months ago
Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
👍️0
Firestorm22 Firestorm22 11 months ago
Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
👍️0
ErnieBilco ErnieBilco 11 months ago
I'm in at 33 cents so I'm not going anywhere, just gonna let it ride wherever it goes
👍️ 1
Firestorm22 Firestorm22 11 months ago
Thanks, I’m hanging onto it . With actual revenues of 40-60 mill the last 5 quarters, one would think this stock price should rise. I wouldn’t mind seeing them bought out.
👍️ 1
ErnieBilco ErnieBilco 11 months ago
Classic sell the news. Probable offering coming next week to dilute on the good news.
👍️0
Firestorm22 Firestorm22 11 months ago
Something just isnt right here. How do you get FDA approval for a drug and your stock price tank? Is there some bads news getting ready to come out on this company??
👍️0
Krspecialized Krspecialized 11 months ago
Long solid position here!
👍️0
Limey42 Limey42 11 months ago
Long term play. Congrats all!
👍️ 1
dugie100 dugie100 11 months ago
Something didn’t look good , I guess!
👍️0
TrendTrade2016 TrendTrade2016 11 months ago
AKBA should see 3 bucks
👍️0
TrendTrade2016 TrendTrade2016 11 months ago
AKBA...FDA EXPLOSION ...WE LOADED THIS BEAUTY....KOCKED AND LOADED!!!!
👍️0
glenn1919 glenn1919 12 months ago
AKBA...................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 12 months ago
AKBA new 52 hi
👍️0
eyeownu eyeownu 12 months ago
$AKBA looking good damn! she fine.
👍️ 1
glenn1919 glenn1919 12 months ago
AKBA.................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
eyeownu eyeownu 1 year ago
$AKBA from stocktwits FDA’S THREE ALARM FIRE- (a)FDA issued CRL to FibroGen & Roxadustat (Aug. 2021); (b)FDA issued CRL to Akebia & Vadadustat (March 2022); (c)FDA’s Cardiovascular & Renal Drugs Advisory Committee supported GSK’s Daprodustat for dialysis dependent patients w/ anaemia of CKD w/ 13-3 vote (Oct. 2022); (d)Akebia submitted FDRR w/ FDA’s Senior Advisor in agency’s Office of New Drugs (OND) (Nov. 2022); (e)CKD community & key opinion leaders such as Dr. Jay Wish criticize FDA decision making concerning HIF-PHI drugs (March 2022 - present). (FDA knows from data that Daprodustat is inferior to Vadadustat.) FDA’S RESPONSE TO FIRE - (a)FDA met w/ Akebia to discuss appeal & subsequently requested “additional clarifying information” (not ADCOM, not clinical trial, not denial) (Nov. 2022); (b)FDA assigned Dr. Peter Stein, M.D., Director of OND as deciding authority for appeal (Feb. 2023); (c)Dr. Stein provided Akebia/Vadadustat w/ clear path forward to approval (May 2023). GLTA
👍️ 1
Monksdream Monksdream 1 year ago
AKBA 10Q March 4
👍️0
Tyrus603 Tyrus603 1 year ago
Excellent chart. Thank you for posting.

Found myself studying it for quite a bit.

As it really is a dream chart for both swing traders AND long term buy & hold investors alike.
👍️0
glenn1919 glenn1919 1 year ago
AKBA..............................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
eyeownu eyeownu 1 year ago
$AKBA
👍️0
eyeownu eyeownu 1 year ago
$AKBA reversal incoming?
👍️0
eyeownu eyeownu 1 year ago
CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has closed a loan facility with funds and accounts managed by BlackRock. The loan provides Akebia with up to $55.0 million of borrowing capacity available in three tranches.

At the closing, Akebia drew the first tranche of $37.0 million and used the proceeds to pay down $35.0 million of principal outstanding from a loan agreement with Pharmakon Advisors, LP (Pharmakon), the investment manager of the BioPharma Credit funds, plus interest and fees. The new agreement substantially extends the interest-only period in the event of vadadustat approval by the U.S. Food and Drug Administration (FDA) without requiring any principal repayment until December 31, 2025, with an option for Akebia to extend until December 31, 2026.
👍️0
eyeownu eyeownu 1 year ago
$AKBA profit taking! hope you took some off the table!
👍️0

Your Recent History

NASDAQ
AKBA
Akebia Therapeutics
BOV
EZTC3
EZTEC ON
BIT
UB5LX2
Unicredit Bank
BIT
F23609
Vontobel Financial Produ...
BIT
P1TR83
BNP Paribas Issuance
BIT
1BOD
Borussia Dortmund KGAA
BIT
RN
Risanamento
BOV
ENAT3Q
ENAUTA ON
BOV
FIQE3Q
Unifique Telecomunicacoes ON
BOV
X1YZ34
Block
BIT
UC4AYR
Unicredit Bank
BIT
UC4VCQ
Unicredit Bank
BIT
3DGL
Etf
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads